Skip to main content
. 2013 Aug 13;8(8):e71679. doi: 10.1371/journal.pone.0071679

Figure 5. AFSC are retained within fibrotic lesions and migrate toward increased CCL2 concentrations.

Figure 5

(A) Sections from lungs injured with bleomycin and injected with CM-Dil labeled AFSC 14 days post bleomycin injury, stained with Sirius Red/FCF Green and DAPI and visualized at 10× show increased retention of AFSC within fibrotic lesions (arrows). (B) Cultured human and murine AFSC express CCR2, the cognate receptor for CCL2, visualized by immunofluorescence. Scale bar = 50 µm. (C) Murine AFSC migrate toward a recombinant CCL2 gradient. (D) Migration elicited by CCL2 in human AFSC toward recombinant CCL2. (E) AFSC migration toward BAL harvested at day 3 from control, bleomycin-injured versus bleomycin-injured with AFSC treatment at day 0, assayed for the ability to chemoattract AFSC (gray boxes). Migration toward BAL with CCL2 neutralized using a neutralizing antibody (Nab) elicited a diminished migratory response in AFSC (hashed boxes). Distributions are presented as box plots with lines at the lower quartile, median and upper quartile, whiskers are representative of the minimum and maximums excluding outliers, dots are representative of outliers. (F) AFSC migration toward BAL samples harvested at the 28-day time point having either received no treatment, or treatment at days 0 or 14. Distributions are presented as box plots with lines at the lower quartile, median and upper quartile, whiskers are representative of the minimum and maximums excluding outliers, dots are representative of outliers.